Effects of PD-1 blockade on bone health and cancer spread
Official title: PD-1 blockade effects on bone strength and metastatic progression
Funded at Vanderbilt University · NIH-10988974 · Data updated 2026-11-12
This study is looking at how blocking a protein called PD-1 might help strengthen bones and slow down cancer that has spread to them, especially for patients dealing with bone metastases, by understanding how immune cells affect bone health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $35,870 |
| NIH project number | 1F99CA294171-01 |
| Project ID | NIH-10988974 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancer that has metastasized to the bones, particularly those undergoing treatment with immune checkpoint inhibitors.
✕Less likely to help
Patients without bone metastases or those not receiving immune checkpoint inhibitors may not benefit from this research.
What this research studies
This research investigates how blocking the PD-1 protein, which is involved in immune responses, affects bone strength and the progression of cancer that has spread to the bones. The study will explore the relationship between immune cells and bone loss, particularly in patients with bone metastases. By examining how these immune cells behave after PD-1 blockade, the research aims to uncover mechanisms that lead to bone deterioration and cancer resistance in the bone environment. This could help identify new strategies to improve treatment outcomes for patients with bone metastases.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies that protect bone health in cancer patients receiving immune checkpoint inhibitors.
How similar studies have gone: Previous research has shown that immune checkpoint inhibitors can have adverse effects on bone health, indicating that this area of investigation is both relevant and necessary.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Joseph, Gwenyth Jean — Vanderbilt University
- Study coordinator: Joseph, Gwenyth Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.